Why Are People Filing Mounjaro Lawsuits?
People choose to file a Mounjaro claim to seek compensation after experiencing unexpected and severe side effects. They may have started the medication to manage type 2 diabetes or lose weight without realizing their full risks.
Mounjaro lawsuits allege that Eli Lilly & Company:
- Failed to warn doctors and patients about severe side effects
- Had a duty to inform consumers and health care providers about adverse reactions
- Knew or should have known about serious symptoms
Women may be especially affected since they’re more likely than men to take GLP-1 medications like Mounjaro. According to KFF, 15% of women are currently taking a GLP-1, compared to 9% of men.
If you or a loved one took Mounjaro (tirzepatide) and suffered a serious injury, you may be able to pursue compensation. Our compassionate team can help you understand your legal options.
See if you qualify for a Mounjaro claim now.
What Are Mounjaro Side Effects?
Common tirzepatide side effects like nausea and diarrhea are listed on Mounjaro’s warning label, but ongoing medical product liability claims cite other serious reactions that weren’t disclosed
Side effects of Mounjaro can include:
- Gallbladder inflammation
- Gastroparesis (stomach paralysis)
- Ileus (bowel blockage)
- Pancreatitis
- Severe nausea and vomiting
- Sudden vision loss from non-arteritic anterior ischemic optic neuropathy (NAION)
Mounjaro lawsuits seek to recover compensation for people who experienced one or more of these symptoms, either through an out-of-court settlement or verdict.
Who Qualifies for a Mounjaro Lawsuit?
You may be eligible for a Mounjaro claim if you took the drug and were later diagnosed with a serious gastrointestinal (GI) injury or other Mounjaro long-term side effects. Each case is different, so your medical history matters.
You could qualify to file a Mounjaro lawsuit if you:
- Have proof that you were prescribed the medication
- Didn’t know of possible serious side effects when you started Mounjaro
- Got diagnosed with one or more adverse reactions to the medication
- Required ongoing medical care or hospitalization due to Mounjaro side effects
Don’t worry if you’re not sure about your eligibility. We’ll listen to your story and help you figure out if you qualify to work with a Mounjaro lawyer and seek compensation.
Contact us now to take the first step toward a Mounjaro lawsuit.
Mounjaro Lawsuit Updates
As of October 2026, there are 2 federal multidistrict litigations (MDLs) centered on Mounjaro. One is specifically for those with GI injuries, while the other is for patients who lost their vision after taking Mounjaro.
These MDLs consolidate similar Mounjaro claims to simplify the legal process for those involved, while still allowing individual financial payouts for each case.
Here are the latest Mounjaro lawsuit updates:
- October 1, 2026: The GI injury MDL (3094) has 4,025 active claims. The vision loss MDL (3163) rose to 247 pending claims as more people have come forward with vision loss lawsuits.
- August 28, 2026: The U.S. Food and Drug Administration (FDA) posted an updated Mounjaro label that notes the drug’s potential ability to reduce the risk of heart attacks and strokes. The new label also warns of potential increases in digestive enzymes produced by the pancreas.
- December 15, 2025: The vision loss MDL 3163 began, consolidating 29 similar claims.
- August 4, 2023: A Louisiana woman sued Eli Lilly & Company over severe vomiting that started after she began Mounjaro. She eventually required hospitalization and lost some of her teeth.
- March 14, 2024: The initial U.S. Judicial Panel on Multidistrict Litigation hearing for MDL 3094 happened in the Eastern District of Pennsylvania. Eli Lilly & Company was one of the manufacturers named in weight loss drug lawsuits consolidated in the MDLs.
There’s still time for you to file a Mounjaro claim. As these MDLs move forward, the rulings could shape what happens next for other people who suffered after trusting Mounjaro to help them manage their blood sugar levels or lose weight.
Mounjaro Lawsuit Settlement Amounts
There hasn’t been a Mounjaro lawsuit payout yet, as of October 2026. The MDLs are still in pretrial stages, and no trial dates have been announced.
Mounjaro lawsuit payouts per person will depend on:
- Any lost income connected to Mounjaro side effects
- Each person’s age and health
- Medical costs of treating adverse reactions
- The severity of the injury
- Whether the injury is permanent
Compensation may still be available even without any previous settlements. Our partner weight loss drug lawyers have recovered $1.6 billion to date for people who were injured or harmed by other dangerous drugs.
How Mounjaro Lawsuit Compensation Could Help
Unexpected Mounjaro side effects can change your daily life. You may need help driving, working, or taking care of responsibilities that you used to manage without assistance.
Mounjaro lawsuit settlement amounts may help you cover:
- Assistive devices
- Emotional distress
- Lost wages
- Medical bills
- Ongoing vision care
- Reduced quality of life
- Other related medical expenses
Compensation from a Mounjaro claim isn’t guaranteed, and every case is unique. However, a settlement or verdict could ease your financial stress and improve your quality of life.
How to File a Mounjaro Lawsuit
You don’t have to file a weight loss drug claim alone. Our partner Mounjaro lawsuit lawyers can speak with you about your experience and navigate the legal system for you while you rest at home.
Here’s how you can file a Mounjaro lawsuit:
- Get a free case review: Talk with us about what happened to you and see if you may qualify.
- Gather evidence: Your Mounjaro attorney will collect your prescription records, pharmacy receipts, and test results as needed to strengthen your case.
- File before the deadline: Your lawyer will work to file your lawsuit within your state’s statute of limitations, which is the time limit to submit your claim.
- Let your lawyer handle everything: They’ll work to pursue a fair settlement or verdict in the event that the case goes to court.
Every state has its own deadline for these claims, so it’s important to act quickly. The sooner you reach out, the more time your legal team has to build your case.
How Long Do You Have to File a Mounjaro Lawsuit?
Your state’s statute of limitations, which is a legal deadline, sets how long you have to file a Mounjaro claim after adverse reactions. In most cases, the countdown begins when you learn of your injury or connect it to your prescription, rather than the day you started taking the medication.
People typically have 2 to 3 years to file their Mounjaro lawsuits, but some states only give people 1 year to submit a claim.
Because these deadlines differ from state to state and courts enforce them strictly, it’s best to check whether you qualify right away.
Reach out to us today to learn more.
Get Help With Your Mounjaro Lawsuit
You trusted Mounjaro to help you lose weight or manage your type 2 diabetes. If it left you with vision loss, a serious GI injury, or another medical complication, you deserve answers and support.
Her Case Matters helps women understand their rights in these cases. If you’re eligible, we can connect you with one of our Mounjaro lawsuit attorneys. The lawyers in our network are highly experienced, and because they charge no upfront or hourly fees, there’s no risk to work with them.
Get a free case review or call (877) 640-6101 now to discuss filing a Mounjaro lawsuit.
Mounjaro Lawsuit FAQs
Is there a lawsuit against Mounjaro?
Yes, many Mounjaro lawsuits have been filed in federal court and grouped into 2 main multidistrict litigations (MDLs). They’re ongoing, so payouts haven’t happened yet. Our team is closely monitoring the MDLs to give families a better idea of when to expect compensation.
Here’s how the 2 Mounjaro MDLs compare:
- MDL 3094: This combined lawsuits that claim GLP-1 drugs like Mounjaro and Ozempic® caused adverse and unexpected GI complications.
- MDL 3163: This Mounjaro blindness lawsuit alleges that GLP-1 drugs caused vision loss (NAION), which may be permanent.
Both MDLs are overseen by U.S. District Judge Karen S. Marston in the Eastern District of Pennsylvania. They continue to move forward with bellwether trials, which means there’s still time to join.
Contact us now to learn if you’re eligible to file based on your Mounjaro side effects.
What are the long-term effects of Mounjaro?
Mounjaro claims cite serious symptoms that people say they weren’t aware of when they started taking the weight loss drug.
While the medication can cause common side effects like stomach cramping and diarrhea, some people allege they’ve had complications with permanent effects.
Serious long-term Mounjaro side effects include:
- Bowel obstructions (ileus)
- Inflammation in the gallbladder
- Pancreatitis
- Severe vomiting or nausea
- Stomach paralysis (gastroparesis)
- Sudden vision loss (NAION)
- Other gastrointestinal issues
Many of these conditions require ongoing treatment, hospitalization, or surgery, which Mounjaro settlements can help cover. You didn’t deserve what happened to you, and you shouldn’t have to manage related costs out of pocket.
Can Mounjaro affect eyesight?
Yes, Mounjaro can potentially impact eyesight. Many patients have complained that they developed non-arteritic anterior ischemic optic neuropathy, known as NAION, after using Mounjaro. NAION can potentially lead to vision damage.
Some of those patients filed Mounjaro lawsuits, which are now part of MDL 3163. The federal lawsuit consolidates NAION vision loss claims made by people who were taking weight loss medications.
As of October 2026, 247 cases were pending in this MDL. There may still be time for others to join, depending on each person’s medical history and vision loss severity.
Is there a Mounjaro class action lawsuit?
No, most Mounjaro cases are part of MDLs, which are different from class action lawsuits. In an MDL, similar cases are grouped for pretrial steps, but each victim’s case is still reviewed on its own facts. Settlements are determined based on case-specific factors.
A class action lawsuit combines identical claims and divides compensation equally among them. Both can lead to settlements or verdicts, but they split payouts differently.
While there have been no Mounjaro legal payouts yet, MDLs may allow you to get a fairer payout that’s specific to your injuries rather than if the cases were filed as class actions.
How much are Mounjaro lawsuit settlement payouts?
There haven’t been any Mounjaro lawsuit settlements or verdicts yet, but the cases are ongoing. Both MDLs are proceeding with bellwether trials, and compensation could vary for each.
Our team can help you understand what your claim may be worth. Get your free case review now to get answers and decide what you want to do next.
Written by: Her Case Matters
At HerCaseMatters, we believe women deserve to be heard — especially when it comes to their health and safety. Too often, harmful drugs, devices, and corporate wrongdoing impact women’s lives without proper warning, support, or accountability. We’re here to change that. We work with trusted legal partners who are deeply experienced in holding powerful companies accountable. But more than that, we’re here to remind women everywhere that their pain is real, their experiences matter, and they deserve justice.
- AJMC. (August 28, 2026). FDA expands tirzepatide label to reduce cardiovascular risk in type 2 diabetes. Retrieved from: https://www.ajmc.com/view/fda-expands-tirzepatide-label-to-reduce-cardiovascular-risk-in-t2d.
- CBS News. (March 13, 2024). Philadelphia federal court will have its first hearing about the safety of Ozempic. Retrieved from: https://www.cbsnews.com/philadelphia/news/ozempic-class-action-lawsuit-philadelphia-federal-court-first-hearing/.
- Karrar, H. R., Nouh, M. I., Nouh, Y. I., et al. (September 27, 2023). Tirzepatide-induced gastrointestinal manifestations: A systematic review and meta-analysis. Retrieved from: https://www.cureus.com/articles/170540-tirzepatide-induced-gastrointestinal-manifestations-a-systematic-review-and-meta-analysis#!/.
- KFF. (November 14, 2025). Poll: 1 in 8 adults say they are currently taking a glp-1 drug for weight loss, diabetes or another condition, even as half say the drugs are difficult to afford. Retrieved from: https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/.
- Reuters. (December 15, 2025). Lawsuits claiming Ozempic, other GLP-1s led to blindness become second mass litigation over the drugs. Retrieved from: https://www.reuters.com/legal/government/lawsuits-claiming-ozempic-other-glp-1s-led-blindness-become-second-mass-2025-12-15/.
- Sokolove Law. (September 10, 2026). Mounjaro® Lawsuit. Retrieved from: https://www.sokolovelaw.com/dangerous-drugs/ozempic/mounjaro/.
- United States District Court, Eastern District of Pennsylvania. (n.d.). MDL 3094 in re: Glucagon-like peptide-1 receptor agonists (GLP-1 RAS) products liability litigation (GI injuries). Retrieved from: https://www.paed.uscourts.gov/mdl/mdl-3094-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-products-liability-litigation-gi.
- United States District Court, Eastern District of Pennsylvania. (n.d.). MDL 3163 in re: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) non-arteritic anterior ischemic optic neuropathy (NAION) products liability litigation. Retrieved from: https://www.paed.uscourts.gov/mdl/mdl-3163-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-non-arteritic-anterior-ischemic-optic.
- United States Judicial Panel on Multidistrict Litigation. (January 5, 2026). MDL statistics report – Distribution of pending MDL dockets by actions pending. Retrieved from: https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-January-5-2026.pdf.
- United States Judicial Panel on Multidistrict Litigation. (October 1, 2026). MDL statistics report – Distribution of pending MDL dockets by actions pending. Retrieved from: https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-October-1-2026.pdf.
